Literature DB >> 22285858

Hypoxia-induced up-regulation of apelin is associated with a poor prognosis in oral squamous cell carcinoma patients.

Kyun Heo1, Yun Hee Kim, Ho Jin Sung, Hai Ying Li, Chong Woo Yoo, Joo Young Kim, Joo Yong Park, Ui Lyong Lee, Byung Ho Nam, Eun Ok Kim, So Young Kim, Seung Hoon Lee, Jong Bae Park, Sung Weon Choi.   

Abstract

Recently, apelin has been shown to be a novel angiogenic factor in various cancers including lung, breast and brain cancer. However, there is limited information regarding the expression and role of apelin in oral cavity cancer. In this study, we determined that apelin expression was localized in the cytoplasm of oral squamous cell carcinoma at various intensities. Strong apelin expression significantly correlated with tumor recurrence and disease-free survival. Using a multivariate analysis, we demonstrated that apelin was an independent prognostic factor for on disease-free survival, age, lymph node metastasis and CA9 expression. Moreover, apelin expression was up-regulated under hypoxic conditions, and exogenous apelin enhanced the proliferation and migration of oral cancer cells. Based on these results, we propose that the presence of hypoxia-induced apelin is a new prognostic factor and potential therapeutic target for oral squamous cell carcinoma.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22285858     DOI: 10.1016/j.oraloncology.2011.12.015

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  40 in total

Review 1.  Hypoxic tumor microenvironment: Implications for cancer therapy.

Authors:  Sukanya Roy; Subhashree Kumaravel; Ankith Sharma; Camille L Duran; Kayla J Bayless; Sanjukta Chakraborty
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-27

2.  Protamine is an antagonist of apelin receptor, and its activity is reversed by heparin.

Authors:  Sophie Le Gonidec; Carline Chaves-Almagro; Yushi Bai; Hye Jin Kang; Allyson Smith; Estelle Wanecq; Xi-Ping Huang; Hervé Prats; Bernard Knibiehler; Bryan L Roth; Larry S Barak; Marc G Caron; Philippe Valet; Yves Audigier; Bernard Masri
Journal:  FASEB J       Date:  2017-02-27       Impact factor: 5.191

3.  Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth.

Authors:  Chad Hall; Laurent Ehrlich; Julie Venter; April O'Brien; Tori White; Tianhao Zhou; Tien Dang; Fanyin Meng; Pietro Invernizzi; Francesca Bernuzzi; Gianfranco Alpini; Terry C Lairmore; Shannon Glaser
Journal:  Cancer Lett       Date:  2016-11-26       Impact factor: 8.679

4.  Multifunctional APJ Pathway Promotes Ovarian Cancer Progression and Metastasis.

Authors:  Deepika Neelakantan; Samrita Dogra; Bharat Devapatla; Pharavee Jaiprasart; Marie Claire Mukashyaka; Ralf Janknecht; Shailendra Kumar Dhar Dwivedi; Resham Bhattacharya; Sanam Husain; Kai Ding; Sukyung Woo
Journal:  Mol Cancer Res       Date:  2019-03-11       Impact factor: 5.852

5.  SCNH2 is a novel apelinergic family member acting as a potent mitogenic and chemotactic factor for both endothelial and epithelial cells.

Authors:  Changge Fang; Ingalill Avis; Caterina Bianco; Natalie Held; Jennifer Morris; Kris Ylaya; Stephen M Hewitt; Alfred C Aplin; Roberto F Nicosia; Laura A Fung; John D Lewis; William G Stetler-Stevenson; David S Salomon; Frank Cuttitta
Journal:  Open J Clin Diagn       Date:  2013-06

6.  Elevation of serum apelin-13 associated with proliferative diabetic retinopathy in type 2 diabetic patients.

Authors:  Jun-Hui Du; Xia Li; Rong Li; Lin Xu; Ran-Ran Ma; Song-Fang Liu; Zhong Zhang; Hong-Zhi Sun
Journal:  Int J Ophthalmol       Date:  2014-12-18       Impact factor: 1.779

7.  Association of leptin, visfatin, apelin, resistin and adiponectin with clear cell renal cell carcinoma.

Authors:  Hai-Ping Zhang; Jian Zou; Zhuo-Qun Xu; Jun Ruan; Shu-Dong Yang; Ying Yin; Hui-Jun Mu
Journal:  Oncol Lett       Date:  2016-11-22       Impact factor: 2.967

8.  Evaluation of Apelin/APJ system expression in hepatocellular carcinoma as a function of clinical severity.

Authors:  Manuela Cabiati; Melania Gaggini; Paolo De Simone; Silvia Del Ry
Journal:  Clin Exp Med       Date:  2020-11-17       Impact factor: 3.984

9.  Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation.

Authors:  Antonio Lacquaniti; Giuseppe Altavilla; Antonio Picone; Valentina Donato; Valeria Chirico; Patrizia Mondello; Carmela Aloisi; Grazia Marabello; Saverio Loddo; Antoine Buemi; Giuseppina Lorenzano; Michele Buemi
Journal:  Clin Exp Med       Date:  2014-01-28       Impact factor: 3.984

10.  Emerging role of adipokine apelin in hepatic remodelling and initiation of carcinogensis in chronic hepatitis C patients.

Authors:  Rola M Farid; Riham M Abu-Zeid; Ahmed El-Tawil
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.